TICKERNERD
Menu
AVLNHealthcare · Biotechnology

AVLN Stock Forecast: Avalyn Pharma, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$38
−1.85% on the day

The 4 Wall Street analysts covering Avalyn Pharma, Inc. hold a median 12-month price target of $59 — +55.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.7B
Ticker Nerd rank
1 / 100
Median analyst target
$59
Analysts covering
4
Total return, dividends reinvested
1W
−1.5%
1M
+34.7%
From high
−4.1%
From low
+46.7%
$26
$39
Range since 30 Apr 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

AVLN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Avalyn Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
1 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
39
Momentum
33
Revisions
27
Value
12
Growth
8
Accruals
8
Issuance
6
Quality
4
Volatility
4

Size (39): Smaller than most of the companies we track.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AVLN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AVLN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 30 Apr 2026Adjusted close, US dollars
$20$30$40$50$60$70$80May 26Jun 26Jul 26Aug 26AVLNHigh $80Median $59Low $52

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $52Median $59High $80

The green dot is the last close — the median target sits +55.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2026Morgan StanleyMaintainsOverweight$53 → $57
26 May 2026Evercore ISI GroupInitiatesOutperform$51
26 May 2026Evercore ISI GroupInitiatesOutperform—
26 May 2026GuggenheimInitiatesBuy—
26 May 2026GuggenheimInitiatesBuy$80
26 May 2026Morgan StanleyInitiatesOverweight$53
26 May 2026Morgan StanleyInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVLN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AVLN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Avalyn Pharma, Inc. (AVLN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−18.8×

Cheaper than 95% of US stocks

Price / sales
—
Price / book
4.3×

Cheaper than 26% of US stocks

EV / EBITDA
−12.4×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
35.7%

Higher than 90% of US stocks

Return on assets
−57.2%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AVLN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AVLNAvalyn Pharma, Inc.$1.7B
1
SNDXSyndax Pharmaceuticals, Inc.$1.7B
64
ANABAnaptysBio, Inc.$1.7B
100
FTREFortrea Holdings, Inc.$1.7B
97
VIRVir Biotechnology, Inc.$1.6B
93
FBRXForte Biosciences, Inc.$1.6B
34
MAZEMaze Therapeutics, Inc.$1.6B
19

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Avalyn Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AVLN news & analysis

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

GlobeNewsWire · 24 Aug 2026neutral

Avalyn announced multiple presentations at the European Respiratory Society International Congress 2026. The presentations describe the integration of the patient perspective into clinical trial design and data modeling of AP01 distribution in the lungs.

Why it matters — An AVLN watcher would care because the presentations highlight the company's progress and scientific engagement around its lead candidate AP01 and its clinical trial approach.

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewsWire · 12 Aug 2026positive

Avalyn Pharma reported its second quarter 2026 financial results, including $413.5 million in cash and marketable securities with a projected runway into 2029. The company completed global enrollment in the MIST Phase 2b trial of AP01 with 398 patients, with topline data expected in the second half of 2027, and had two abstracts accepted for presentation at the European Respiratory Society Congress.

Why it matters — Avalyn watchers would follow this as it confirms progress of the AP01 program toward its upcoming data readout and provides a view of the company's cash position and funding runway.

FAQ

Frequently asked questions about AVLN stock

What is the AVLN stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Avalyn Pharma, Inc. have a median 12-month price target of $59, with estimates ranging from $52 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AVLN stock a buy right now?

Of the 4 analysts covering Avalyn Pharma, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Avalyn Pharma, Inc. 1 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AVLN?

As at 22 Aug 2026, Avalyn Pharma, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (39 of 100).

Will AVLN stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +55.3% from the last close, and Ticker Nerd's factor model ranks Avalyn Pharma, Inc. 1 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AVLN stock forecast for 2030?

No analyst covering Avalyn Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVLN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $52 to $80 over the next 12 months.

What does Avalyn Pharma, Inc. do?

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.

What is the latest news on AVLN?

The most recent item we track (GlobeNewsWire, 24 Aug 2026): "Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026". Avalyn announced multiple presentations at the European Respiratory Society International Congress 2026. The presentations describe the integration of the patient perspective into clinical trial design and data modeling of AP01 distribution in the lungs.

Company

About Avalyn Pharma, Inc.

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. Its pipeline features optimized inhaled formulations of established antifibrotic medicines, such as AP01, an inhaled version of pirfenidone for progressive pulmonary fibrosis, and AP02, an inhaled formulation of nintedanib for idiopathic pulmonary fibrosis. This nebulization approach aims to deliver medication directly to the lung tissue, potentially improving efficacy while reducing the significant side effects and tolerability issues associated with current oral therapies that often limit patient compliance. Avalyn Pharma Inc. focuses on addressing the unmet needs in treating these progressive conditions by enhancing local drug delivery and minimizing systemic exposure. Founded in 2011 and headquartered in Boston, Massachusetts, the company operates in the biopharmaceutical sector targeting serious rare lung disorders.

CEO Ms. Lyn Baranowski · 55 employees · United States · https://www.avalynpharma.com